Virus vert dégradé

Santé Active Edition – Synergy Pharm: Medical Writing Solutions

We have been serving the pharmaceutical industry, and more generally the scientific research community, for more than 30 years.

We work accurately and efficiently to meet your deadlines, while our compliance with international standards (CONSORT, ICH, etc.), systematic proofreading between medical writers, and attention to detail guarantee that your documents will be of the highest quality. Our adaptability and responsiveness lead us to develop privileged and ongoing relationships with our clients.

Our latest news

Logo Synergy Pharm - Santé Active Edition
news

European Patients’ Rights Day

April 18 is European Patients’ Rights Day (EPRD).

More specifically, this charter proclaims:

  • The right to information (“access to all that scientific research and technological innovation makes available”),
  • The right to consent for any procedure or treatment, but also for participation in clinical trials,
  • The right to innovation (“right of access to innovative procedures, including diagnostic procedures”), which implies the right of access to treatments or medical devices assessed in clinical trials.

The European Clinical Trials Regulation (Regulation (EU) No 536/2014) also aims to guarantee the rights of patients, and all of the medical writers at Synergy Pharm/Santé Active Edition are committed to ensuring that information relating to compliance with ethical standards and good clinical practice is clearly stated in publications reporting the results of clinical trials.

news

French “Week Against Cancer” 2022

On the occasion of the national “Week Against Cancer” campaign in France, it is important to highlight research efforts aimed at reducing the side effects associated with cancer treatments.

Indeed, while the range of treatments available – used alone or in combination – are effective against cancer, they can have many side effects, particularly on the skin. Xerosis is one of the most frequent side effects of cancer therapy and requires appropriate management to help maintain patient quality of life and prevent potential interruptions to cancer treatment.

A recent multicenter, real-world, phase IV study demonstrated the benefits of using an emollient containing a postbiotic in the management of 319 patients with xerosis associated with a range of cancer treatments (chemotherapy, targeted therapy, radiotherapy, hormonotherapy and immunotherapy).

A previous multicentre, real-world, phase IV study had already demonstrated the effectiveness of this emollient for the management of xerosis in 5,910 patients with a range of skin conditions (atopic dermatitis, senile xerosis, ichthyosis, psoriasis, prurigo nodularis of Hyde etc.) and underlying systemic conditions (diabetes mellitus, thyroid disease, renal insufficiency, etc.).

These two articles, published in Dermatology and Therapy and written by our medical writing team, can be found here:

news

Brain Awareness Week 2022

*Learning, Brain and Artificial Intelligence, Brain and New Technologies, Brain and Society, Brain and Sport, Sleep, The 5 senses, Emotions, Memory, The Sick Brain.

See all our news